{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(15)"],"submitter":["Abolhalaj M"],"funding":["Vetenskapsrådet","Lunds Tekniska Högskola, Lunds universitet","Mats Paulssons Stiftelse","VINNOVA","Fondation ISREC","Cancerfonden"],"pubmed_abstract":["<h4>Background</h4>Acute myeloid leukemia (AML) patients have limited effect from T-cell-based therapies, such as PD-1 and CTLA-4 blockade. However, recent data indicate that AML patients with TP53 mutation have higher immune infiltration and other immunomodulatory therapies could thus potentially be effective. Here, we performed the transcriptional analysis of distinct T-cell subpopulations from TP53-mutated AML to identify gene expression signatures suggestive of altered functional properties.<h4>Methods</h4>CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs), conventional helper T cells (Th), and regulatory T cells (Tregs) were sorted from peripheral blood of AML patients with TP53 mutation (n = 5) and healthy donors (n = 3), using FACS, and the different subpopulations were subsequently sub"],"journal":["Cancer medicine"],"pagination":["3023-3032"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9359873"],"repository":["biostudies-literature"],"pubmed_title":["Transcriptional profiling demonstrates altered characteristics of CD8<sup>+</sup> cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia."],"pmcid":["PMC9359873"],"pubmed_authors":["Hagerbrand K","Sincic V","Aab A","Fioretos T","Sanden C","Borrebaeck CAK","Lundberg K","Abolhalaj M","Ellmark P","Lilljebjorn H"],"additional_accession":[]},"is_claimable":false,"name":"Transcriptional profiling demonstrates altered characteristics of CD8<sup>+</sup> cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia.","description":"<h4>Background</h4>Acute myeloid leukemia (AML) patients have limited effect from T-cell-based therapies, such as PD-1 and CTLA-4 blockade. However, recent data indicate that AML patients with TP53 mutation have higher immune infiltration and other immunomodulatory therapies could thus potentially be effective. Here, we performed the transcriptional analysis of distinct T-cell subpopulations from TP53-mutated AML to identify gene expression signatures suggestive of altered functional properties.<h4>Methods</h4>CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs), conventional helper T cells (Th), and regulatory T cells (Tregs) were sorted from peripheral blood of AML patients with TP53 mutation (n = 5) and healthy donors (n = 3), using FACS, and the different subpopulations were subsequently sub","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-03-31T11:22:13.576Z","creation":"2025-04-04T19:27:39.143Z"},"accession":"S-EPMC9359873","cross_references":{"pubmed":["35297213"],"doi":["10.1002/cam4.4661"]}}